Despite the conventional belief that lungs are sterile, recent studies have identified a diverse microbial community in the lungs, known as the lung microbiome. The lung microbiome has emerged as a novel area of research in pulmonary medicine and is being increasingly recognized as a key player in the pathogenesis of various lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.
This collection sets out to explore the role of the lung microbiome in health and disease, with a particular emphasis on its potential as a therapeutic target. Manuscripts are sought that examine the composition and function of the lung microbiome, as well as its interactions with the host immune system.
Papers are also welcome that investigate the role of the lung microbiome in the development and progression of lung diseases, including studies on the effects of environmental factors and lifestyle on the lung microbiome. We welcome submissions that explore the potential of novel therapies targeting the lung microbiome, such as probiotics, prebiotics, and fecal microbiota transplantation.
Manuscripts that discuss the implications of the lung microbiome on personalized medicine and precision health are also encouraged, as are papers that examine the role of the lung microbiome in the response to therapies for lung diseases.
We welcome submissions from researchers and practitioners in the fields of pulmonary medicine, microbiology, immunology, and bioinformatics. Manuscripts that employ a range of methodologies, including clinical trials, observational studies, and mechanistic studies, are welcome.
